2-((R)-1-{3-[4-(3,5-dimethoxy-phenyl)-7-oxo-1,2,3,7-tetrahydro-pyrrolo[2,3-d]pyridazin-6-yl]-4-trifluoromethyl-phenyl}-pyrrolidin-3-yl)-N-methyl-acetamide | 937193-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-((R)-1-{3-[4-(3,5-dimethoxy-phenyl)-7-oxo-1,2,3,7-tetrahydro-pyrrolo[2,3-d]pyridazin-6-yl]-4-trifluoromethyl-phenyl}-pyrrolidin-3-yl)-N-methyl-acetamide
• 英文别名: 2-[(3R)-1-[3-[4-(3,5-dimethoxyphenyl)-7-oxo-2,3-dihydro-1H-pyrrolo[2,3-d]pyridazin-6-yl]-4-(trifluoromethyl)phenyl]pyrrolidin-3-yl]-N-methylacetamide
• CAS: 937193-04-9
• 化学式: C₂₈H₃₀F₃N₅O₄
• 分子量: 557.573
• InChiKey: HIPKYNKTIHCJAN-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  95.5
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF
  申请人：Japan Tobacco, Inc.

  公开号：EP1953147A1

  公开（公告）日：2008-08-06

  The present invention aims at providing a novel heterocyclic compound having HCV entry inhibitory activity and the pharmaceutical use thereof. The present invention provides a therapeutic agent for hepatitis C comprising a heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient: wherein Q1 is -N=, etc., Q2 is -N-, etc., Q3 is -N=, etc., Q4 is -N-, etc., Q5 is -N-, etc., R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., ring A is a monocyclic aryl group optionally having substituent(s), etc., and ring B is a monocyclic aryl group optionally having substituent(s), etc.

  本发明旨在提供一种具有HCV进入抑制活性的新型杂环化合物及其药物用途。本发明提供了一种治疗丙型肝炎的治疗剂，其包括以下式[1]所表示的杂环化合物或其药学上可接受的盐作为活性成分：其中Q1为-N=等，Q2为-N-等，Q3为-N=等，Q4为-N-等，Q5为-N-等，R1为氢原子等，R2为氢原子等，环A为单环芳基，可选地具有取代基等，环B为单环芳基，可选地具有取代基等。